Theorem Clinical Research

United States

Lupus Research Institute holds NYC's first Lupus Trials Fair

Monday, September 15, 2014 12:39 PM

Over 200 patients, families, physicians and scientists came together under one roof last Friday, Sept. 12, to learn, interact and participate in the drive for better lupus treatments at New York City's first Lupus Trials Fair, launched by the Lupus Research Institute (LRI) and the S.L.E. Lupus Foundation.

More... »


Novartis to open Center for Advanced Cellular Therapeutics at University of Pennsylvania

Monday, September 15, 2014 12:29 PM

The University of Pennsylvania’s alliance with Novartis has unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia.

More... »


Cellerant awarded $47.5M for development of CLT-008 for acute radiation syndrome

Friday, September 12, 2014 01:16 PM

Cellerant Therapeutics, a California biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, has been awarded $47.5 million under a second option exercised by the Biomedical Advanced Research and Development Authority (BARDA) in the office of the assistant secretary for preparedness and response of the department of Health and Human Services.

More... »

PhRMA: 44 medicines and vaccines in development for HIV/AIDS

Friday, September 12, 2014 01:13 PM

America’s biopharmaceutical research companies currently are developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the Washington, D.C.-based Pharmaceutical Research and Manufacturers of America (PhRMA). A second report, The Value of Innovation in HIV/AIDS Therapy, a PhRMA-sponsored white paper by Boston Healthcare Associates (BHA), highlights the progress in HIV/AIDS treatment and its impact on patients afflicted with the disease. 

More... »

Bay Area BioEconomy Initiative appoints Pablo Cagnoni to steering committee

Friday, September 12, 2014 01:01 PM

The Bay Area BioEconomy Initiative (BAB) has named Pablo J. Cagnoni, M.D., president of Onyx Pharmaceuticals, to its steering committee. Onyx, an Amgen subsidiary, is engaged in the development and commercialization of innovative therapies to improve the lives of people with cancer.

More... »

FDA approves weight-management drug Contrave

Friday, September 12, 2014 12:49 PM

The FDA has approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.

More... »

Louis DeGennaro named president, CEO of Leukemia & Lymphoma Society

Thursday, September 11, 2014 03:33 PM

The Leukemia & Lymphoma Society (LLS) has appointed Louis J. DeGennaro, Ph.D., president and CEO, effective immediately.

More... »

MabVax Therapeutics, MSKCC and Juno Therapeutics ink agreement

Thursday, September 11, 2014 01:38 PM

MabVax Therapeutics Holdings, a San Diego-based clinical stage oncology drug development company, has entered into agreements with New York City’s Memorial Sloan-Kettering Cancer Center (MSKCC) and Seattle-based Juno Therapeutics for the development of novel therapeutic products using antibody targeting sequences derived from the fully-human antibodies discovered using the company's internally developed antibody discovery platform.

More... »

PharmAthene awarded $28.1M to develop thermostable anthrax vaccine

Thursday, September 11, 2014 01:36 PM

PharmAthene, an Annapolis, Md.-based biodefense company developing medical countermeasures against biological and chemical threats, has announced the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has awarded the company a contract, valued at up to $28.1 million if all contract options are exercised, for the development of a next-generation anthrax vaccine based on the company's proprietary rPA anthrax vaccine technology platform.

More... »

PMG Research forms its 11th clinical site

Wednesday, September 10, 2014 03:07 PM

PMG Research (PMG), an integrated network of clinical research facilities in the southeastern U.S., has established its 11th clinical research site, PMG Research of Rocky Mount. PMG Research has assumed ownership and operation of the clinical research department at Boice-Willis Clinic in Rocky Mount, N.C., further expanding PMG’s presence in eastern North Carolina. This new site enhances PMG’s access to an additional 130,000 patients.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs